Toxic epidermal necrolysis after treatment with lamotrigine (Lamictal®)

Seizure

Volumn 6, Issue 1, 1997, Pages 63-65

  Fogh, Karsten ^a   Mai, Jesper ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CLOBAZAM; LAMOTRIGINE; PHENOBARBITAL; PREDNISONE; STEROID;

ADULT; ARTICLE; CASE REPORT; DROWSINESS; DRUG EFFICACY; EPILEPSY; FEMALE; HEMATURIA; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; KERATINOCYTE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RASH; SKIN DISEASE; TOPICAL DRUG ADMINISTRATION; TOXIC EPIDERMAL NECROLYSIS;

EID: 0031054475     PISSN: 10591311     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1059-1311(97)80055-6     Document Type: Article

References (16)

1. Lyell, A. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. British Journal of Dermatology 1956; 68: 355-361.
2. Revuz, J., Penso, D. and Roujeau, J.C. Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients. Archives of Dermatology 1987; 123: 1160-1165.
3. Rickens, A. and Yuen, A.W.C. Overview of the clinical efficacy of lamotrigine. Epilpsia 1991; 32 (Suppl. 2): 13-16.
4. Binnie, C.D. The efficacy of lamotrigine. Reviews of Contemporary Pharmacotherapy 1994; 5: 115-122.
5. Pellock, J.M. The clinical efficacy of lamotrigine as an antiepileptic drug. Neurology 1994; 44(Suppl. 8): 29-35.
6. Yuen, A.W.C. Lamotrigine: a review of antiepileptic efficacy. Epilepsia 1994; 35(Suppl. 5): 33-36.
7. Rickens, A. Safety of lamotrigine. Epilepsia 1994; 35(Suppl. 5): 37-40.
8. Guillaume, J.C., Roujeau, J.C., Revuz, J., Penso, D. and Touraine, R. The culprit drugs in 87 cases of toxic epidermal necrolysis (Lyell Syndrome). Archives of Dermatology 1987; 123: 1166-1170.
9. Goa, K.L., Ross, S.R. and Crisp, P. Lamotrigine. A review of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1993; 46: 152-176.
10. Yuen, A. Safety issues. In: Clinical update on lamotrigine: a novel antiepileptic agent. (Ed. Richens, A.) Wells Medical International Clinical Practice series, Turnbridge Wells 1992: pp. 69-75.
11. Schmidt, D. and Kramer, G. The new anticonvulsant drugs. Implications for avoidance of adverse effects. Drug Safety 1994; 11: 422-431.
12. Russo, M., Li, L.M., O'Donoghue, M.F., Sander, J.W.A.S. and Duncan, J.S. Cutaneous rash with lamotrigine and concomitant valproate therapy. Epilepsia 1994; 35(Suppl. 7): 72 (abstract)
13. Bastuji, G.S., Rzany, B., Stern, R.S., Shear, N.H., Daldi, L. and Roujeau, J.C. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson's syndrome and erythema multiforme. Archives of Dermatology 1993; 129: 92-96.
14. Bagot, M., Charue, D., Deslan, M., Weschler, J., Roujeau, J.C. and Revuz, J. Impared antigen presentation in toxic epidermal necrolysis. Archives of Dermatology 1993; 129: 721-727.
15. Wolkenstein, P., Charue, D., Rouleau, J.C., Revuz, J. and Bagot, M. In vitro evaluation of genetic predisposition to toxic epidermal necrolysis. Journal of Dermatological Science 1993; 6: 116 (abstract).
16. Revuz, J., Roujeau, J.C., Guillaume, J.C., Penso, D. and Touraine, R. Treatment of toxic epidermal necrolysis. Creteil's experience. Archives of Dermatology 1987; 123: 1156-1158.